Navigation Links
GW professor discovers new information in the understanding of autism and genetics
Date:1/3/2013

WASHINGTON (Jan. 3, 2012) Research out of the George Washington University (GW), published in the journal Proceedings of the National Academy of Sciences (PNAS), reveals another piece of the puzzle in a genetic developmental disorder that causes behavioral diseases such as autism. Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at the GW School of Medicine and Health Sciences (SMHS) and director of the GW Institute for Neuroscience, along with post-doctoral fellow Daniel Meechan, Ph.D. and Thomas Maynard, Ph.D., associate research professor of pharmacology and physiology at GW SMHS, authored the study titled "Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome."

For the past nine years, LaMantia and his colleagues have been investigating how behavioral disorders such as autism, attention deficit hyperactivity disorder (ADHD), and schizophrenia arise during early brain development. His work published in PNAS focuses specifically on the effects diminished 22q11.2 gene dosage has on cortical circuit development.

This research shows for the first time that genetic lesions known to be associated with autism and other behavioral diseases disrupt cellular and molecular mechanisms that ensure normal development of a key type of cortical neuron: the interneuron. LaMantia and his colleagues had found previously that one type of cortical neuron, the projection neuron, is not generated in appropriate numbers during development in a mouse model of 22q11 Deletion Syndrome. In the current study published in PNAS, LaMantia found that interneurons, while made in the right numbers at their birthplace outside of the cortex, are not able to move properly into the cortex where they are needed to control cortical circuit activity. The research shows that the main reason they don't move properly is due to diminished expression of activity of a key regulatory pathway for migration, the Cxcr4 cytokine receptor.

"This gives us two pieces of the puzzle for this genetic developmental disorder," said LaMantia. "These two pieces tell us that in very early development, those with 22q11.2 deletion syndrome do not make enough cells in one case, and do not put the other cells in the right place. This occurs not because of some degenerative change, but because the mechanisms that make these cells and put them in the right place during the first step of development have gone awry due to mutation."

The next step in LaMantia's research is to probe further into the molecular mechanisms that disrupt the proliferation of projection neurons and migration of interneurons. "If we understand that better and understand its consequences, we can go about fixing it," said LaMantia. "We want to understand why cortical circuits don't get built properly due to the genetic deletion of chromosome 22."


'/>"/>

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University
Source:Eurekalert

Related biology news :

1. National Academy of Inventors names four UT Arlington professors as charter fellows
2. Association of Environmental Engineering and Science Professors name Environmental Engineering Science as its official journal
3. University of Tennessee engineering professor looks to whirligig beetle for bio-inspired robots
4. Increasing drought stress challenges vulnerable hydraulic system of plants, GW professor finds
5. GW professor to examine infections in HIV patients with federal grant
6. Michael Barnett of Boston College named Professor of the Year for Massachusetts
7. NJIT professor promotes building material of millennium: Autoclave aerated concrete
8. The IPCC Report on Climate Change - Swedish professor Thomas Sterner selected as 1 of the experts
9. Louisiana Tech University professor earns national honor from Society of American Foresters
10. New book on physics principles by Wayne State professor explains life as we know it
11. SMU professor Louis Jacobs honored with prestigious award from Texas science teachers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/20/2016)... Dec, 20, 2016   Valencell , the ... and STMicroelectronics (NYSE: STM), a global semiconductor ... applications, announced today the launch of a new, ... wearables that includes ST,s compact SensorTile ... biometric sensor system. Together, SensorTile and Benchmark ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 23, 2017 , ... Edward Buckler, ... recipient of the National Academy of Sciences Prize in Food and Agriculture Sciences. ... , The annual National Academy of Sciences (NAS) Prize in Food and Agriculture ...
(Date:1/24/2017)... 2017 According to a new ... (Genetic, Cell-based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, ... Biotech Companies, CRO) - Global Forecast to 2021", published ... Model Market for the forecast period of 2016 to ... Million by 2021 from USD 73.3 Million in 2016, ...
(Date:1/24/2017)... Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... an underwriting agreement with Rodman & Renshaw, a unit ... sole book running manager and representative of several underwriters, under ... firm commitment basis a minimum of 2,105,264 shares of ... purchase a minimum of 1,052,632 shares of common stock ...
(Date:1/23/2017)... 2017   Enteris BioPharma, Inc. , announced today ... Sanofi to leverage Enteris, proprietary and patented oral ... an oral formulation of one of Sanofi,s preclinical stage ... Executive Officer and Executive Chairman of Enteris BioPharma, remarked, ... tremendous value our Peptelligence platform program offers in the ...
Breaking Biology Technology: